Pathways are still a young enterprise so barriers to their adoption are being more readily recognized than the number of problems being solved are, according to Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.
Pathways are still a young enterprise so barriers to their adoption are being more readily recognized than the number of problems being solved are, according to Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.
Transcript (slightly modified for readability)
What barriers are preventing wider adoption of pathways and how can they be overcome?
There are a number of barriers that we observed to wider adoption of pathways. One of the most important is physician uncertainty. Physicians don't like the concept of cookbook medicine: first you do this, then you do this, then you do something else. Now in many cases that may be the optimal way to help the patient, but if the physician feels there are extenuating circumstances, unique characteristics of that patient, then they want to feel that there is flexibility.
And the good news is that for many of the groups that are monitoring and rewarding physicians for compliance, they're not asking for 100% compliance. Actually the number that we often see is 85%, so that 15% of the patients, for reasons that are clinically very important, different approaches might be necessary.
On the IT front. that's a whole other barrier, which is you see your patient, what are the pathways, what are the things I need to consider. And having electronic health records that would then bring up the pathway and make certain that the elements of the pathway would be reimbursed by the insurance company—there is a lot of barriers related to that.
Pathways are a young enterprise and so the barriers are being more quickly identified than the problems solved.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More